Terms ending in 2037
Every in-force patent on 2SEVENTY Bio, Inc.'s record whose computed term ends in 2037, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,560,547 | Methods of Making T Cell Compositions In force · Medium confidence | 2SEVENTY Bio, Inc. | In force | Medium confidence | |
| US 12,760,099 | Multipartite Signaling Proteins and Uses Thereof In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,006,369 | Bcma Chimeric Antigen Receptors In force · High confidence | 2SEVENTY Bio, Inc. | In force | High confidence | |
| US 11,912,746 | PD-1 Homing Endonuclease Variants, Compositions, and Methods of Use In force · High confidence | Regeneron Pharmaceuticals, Inc. | In force | High confidence | |
| US 12,391,734 | PD-1 Homing Endonuclease Variants, Compositions, and Methods of Use In force · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Medium confidence | |
| US 12,264,343 | TCRa HOMING ENDONUCLEASE VARIANTS In force · Medium confidence | Regeneron Pharmaceuticals, Inc. | In force | Medium confidence |
6 of 6 patents shown. Soonest term end first, then patent number.
2 of these are in force and held by 2SEVENTY Bio, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.